Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 4Sarcoma 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Neuroblastoma 4Medulloblastoma 4Lymphoma, Non-Hodgkin 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 3Sarcoma, Ewing 2Xanthogranuloma, Juvenile 1Lymphoma 1Histiocytic Sarcoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1pembrolizumab 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1cobimetinib 1X-Rays 1Vemurafenib 1Radiation Dose Hypofractionation 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Lenalidomide 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytic Sarcoma × Nuclear Medicine Department, Hospital × Sarcoma × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡